MA34380B1 - Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine - Google Patents

Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Info

Publication number
MA34380B1
MA34380B1 MA35567A MA35567A MA34380B1 MA 34380 B1 MA34380 B1 MA 34380B1 MA 35567 A MA35567 A MA 35567A MA 35567 A MA35567 A MA 35567A MA 34380 B1 MA34380 B1 MA 34380B1
Authority
MA
Morocco
Prior art keywords
derivative
ombrabulin
antitumor
association
platinum
Prior art date
Application number
MA35567A
Other languages
English (en)
Inventor
Patrick Cohen
Ileana Corina Oprea
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10305653A external-priority patent/EP2397135A1/fr
Priority claimed from EP10306256A external-priority patent/EP2481404A1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34380B1 publication Critical patent/MA34380B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platane et son utilisation dans le traitement de tumeurs solides développées.
MA35567A 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine MA34380B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305653A EP2397135A1 (fr) 2010-06-18 2010-06-18 Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
EP10306256A EP2481404A1 (fr) 2010-11-15 2010-11-15 Combinaison antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine
PCT/IB2011/052628 WO2011158206A1 (fr) 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Publications (1)

Publication Number Publication Date
MA34380B1 true MA34380B1 (fr) 2013-07-03

Family

ID=45347705

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35567A MA34380B1 (fr) 2010-06-18 2011-06-16 Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine

Country Status (22)

Country Link
US (1) US20130122113A1 (fr)
EP (1) EP2582369A1 (fr)
JP (1) JP2013528644A (fr)
KR (1) KR20130088753A (fr)
CN (1) CN103140224A (fr)
AR (1) AR082005A1 (fr)
AU (1) AU2011266635A1 (fr)
BR (1) BR112012031917A2 (fr)
CA (1) CA2802974A1 (fr)
CO (1) CO6650420A2 (fr)
DO (1) DOP2012000305A (fr)
EA (1) EA201291268A1 (fr)
EC (1) ECSP12012343A (fr)
MA (1) MA34380B1 (fr)
MX (1) MX2012014732A (fr)
NI (1) NI201200183A (fr)
PE (1) PE20130312A1 (fr)
SG (1) SG186376A1 (fr)
TN (1) TN2012000552A1 (fr)
TW (1) TW201206419A (fr)
UY (1) UY33457A (fr)
WO (1) WO2011158206A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109851593B (zh) * 2019-02-01 2021-04-16 沈阳药科大学 基于淋巴介导转运的甘油三酯前药及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
US20020183266A1 (en) 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Also Published As

Publication number Publication date
PE20130312A1 (es) 2013-03-26
ECSP12012343A (es) 2012-12-28
DOP2012000305A (es) 2013-01-31
KR20130088753A (ko) 2013-08-08
MX2012014732A (es) 2013-01-22
US20130122113A1 (en) 2013-05-16
CN103140224A (zh) 2013-06-05
EP2582369A1 (fr) 2013-04-24
EA201291268A1 (ru) 2013-04-30
WO2011158206A1 (fr) 2011-12-22
SG186376A1 (en) 2013-01-30
TN2012000552A1 (en) 2014-04-01
AR082005A1 (es) 2012-11-07
UY33457A (es) 2012-01-31
JP2013528644A (ja) 2013-07-11
NI201200183A (es) 2013-05-13
AU2011266635A1 (en) 2013-01-10
CA2802974A1 (fr) 2011-12-22
TW201206419A (en) 2012-02-16
BR112012031917A2 (pt) 2017-11-28
CO6650420A2 (es) 2013-04-15

Similar Documents

Publication Publication Date Title
CY1118680T1 (el) Φαρμακευτικη συνθεση
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
TR201708567T4 (tr) Sigma ligandların kemik kanseri ağrısında kullanımı.
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
EA201590987A1 (ru) Соединения и способы их применения
EA201490717A1 (ru) АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
MA34521B1 (fr) Polypeptides de relaxine modifiés et leurs utilisations
PE20151495A1 (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
TR201903981T4 (tr) Kanser tedavisi için bileşikler.
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
EA201290712A1 (ru) Альфа-излучающие комплексы
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201590962A1 (ru) Новые соединения
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
EA201300610A1 (ru) Хиназолинкарбоксамидазетидины
EA201201406A1 (ru) Фунгицидные смеси ii, содержащие хиназолины
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
EA201201670A1 (ru) Циклический амин-азагетероциклический карбоксамид
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MA34709B1 (fr) Compositions pharmaceutiques
MA34380B1 (fr) Association antitumorale comprenant de l'ombrabuline, un dérivé de taxane et un dérivé de platine